Your browser doesn't support javascript.
loading
A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma.
Kollmannsberger, Christian; Choueiri, Toni K; Heng, Daniel Y C; George, Saby; Jie, Fei; Croitoru, Ruslan; Poondru, Srinivasu; Thompson, John A.
Affiliation
  • Kollmannsberger C; University of British Columbia, BC Cancer-Vancouver Cancer Centre, Vancouver, British Columbia, Canada.
  • Choueiri TK; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Heng DYC; University of Calgary, Tom Baker Cancer Center, Calgary, Alberta, Canada.
  • George S; Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Jie F; Astellas Pharma, Inc., Northbrook, Illinois, USA.
  • Croitoru R; Astellas Pharma, Inc., Northbrook, Illinois, USA.
  • Poondru S; Astellas Pharma, Inc., Northbrook, Illinois, USA.
  • Thompson JA; University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Oncologist ; 26(3): 182-e361, 2021 03.
Article in En | MEDLINE | ID: mdl-33289953
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Year: 2021 Type: Article